The natural product industry is booming and showing no signs of slowing. Big brands are taking note by scooping up smaller, innovative companies that are disrupting consumer products by adding a natural twist. Michael Cammarata, Co-Founder and CEO of Schmidt's Naturals, shared why his company was such an attractive target for Unilever.
Cammarata said Unilever was drawn to his brand due to its rapid growth and ability to go to market quickly. He said consumers have been the brands biggest advocate. The entrepreneur also added that the Unilever focuses on the founders and allows them to continue to operate the way they want.
All-natural has been all the rage as consumers increasingly opt for chemical-free products. He says his brand is unique because they focused on competing with brands in the traditional space. He added consumers are realizing products with natural ingredients are delivering similar results as the initial products.
Former Medtronic CEO and author of 'True North' Bill George explains the steps Boeing leadership must take to regain client and consumer trust after 737 Max 9 production was stopped.
Amazon blamed "regulatory hurdles" for calling off its proposed acquisition of robot vacuum maker iRobot. Not even a Roomba could clean up the deal's antitrust scrutiny.
To celebrate Flutter Entertainment's debut on the NYSE, FanDuel CEO Amy Howe shares her thoughts on the company's plans for growth, the future of online sportsbetting, and Super Bowl Sunday.
Investopedia's Caleb Silver shares thoughts on the upcoming Fed meeting, why individual investors are still slightly skeptical, and what he's looking for from mega cap tech earnings.
Season's greetings! Tax season, that is. January 29 is the first day you can file your tax return. We walk you through each step — plus a checklist you can download.
The Q-Collar helps protect athletes from impact-related concussions. Now, the U.S. Army is evaluating if the device could help reduce traumatic brain injury cased by blast weapons.
Co-founder and executive chairman of the board at Vaxxinity Lou Reese shares how the company is working to bring vaccines for chronic illnesses like heart disease and Parkinson’s to market with an eye for accessibility.
Mario Veneroso, Kingsview Asset Management Partner, weighs in on the latest economic data and whether the market is pricing in too many rate cuts for the coming year.
